Hepbest 25mg Tablet

The following are the possible side effects that can occur during your treatment with HepBest 25mg Tablet. Contact your medical practitioner immediately if any of the below-mentioned side effects appear.

Here’s a compiled and paraphrased list of side effects without repetition:

• Headache
•  Dizziness
•  Nausea and vomiting
•  Diarrhea
  
•  Abdominal or stomach pain
  
•  Fatigue and unusual weakness
  
• Insomnia (difficulty sleeping)
•  Fever and cough
• Back pain
• Indigestion
• Joint pain and muscle pain
• Rash or itching (allergic reactions)
• Too much lactic acid in the blood (may cause cold hands/feet, muscle pain, severe weakness)
• Liver problems (yellowing of skin/eyes, dark urine, pale stools, loss of appetite)
• Kidney problems
• Increased risk of bone fractures
  

• Hepbest 25 mg Tablet should be taken according to your physician’s prescription.
• This medication can be taken irrespective of whether you eat food or not, but it is advisable that you take it along with meals.
• You should swallow the tablet whole without crushing or chewing it.
• Make sure never to change the dose of HepBest 25 mg Tablet without consulting your physician first.
  

HepBest 25mg Tablet is an antiviral drug. It is a phosphonamidate prodrug of tenofovir (2’-deoxyadenosine monophosphate analog). It enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3.

It is converted to Tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes. Tenofovir is phosphorylated by cellular kinases to the pharmacologically active metabolite Tenofovir Diphosphate.

Tenofovir Diphosphate works to inhibit HBV replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain termination.

• Zhao, J., Wu, L., Yang, X., Gao, Z., & Deng, H. (2024). Renal function changes in chronic hepatitis B patients. arXiv. https://arxiv.org/abs/2403.02361
  
• Peng, W. T., Jiang, C., Yang, F. L., Zhou, N. Q., Chen, K. Y., Liu, J. Q., Peng, S. F., & Fu, L. (2023). Tenofovir alafenamide versus entecavir for treating hepatitis B virus‑related acute‑on‑chronic liver failure: A real‑world study. Frontiers in Microbiology, 14, Article 1185492. https://doi.org/10.3389/fmicb.2023.1185492.
  
• Li, Y., Li, Y. W., & Gao, Y. (2025). Effect of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide antiviral therapy on renal function in chronic hepatitis B patients: A real‑world retrospective study. International Journal of General Medicine, 18, 1143–1153. https://doi.org/10.2147/IJGM.S497550.
  
• Suda, G., & colleagues. (2023). Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‑related hepatitis. Journal of Medical Virology. Advance online publication. https://doi.org/10.1002/jmv.28452
  
• Chen, A.‑Z., Kang, W., Li, Z.‑H., Chen, D.‑Y., Huang, Q.‑H., & Xu, Q. (2023). Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir. World Journal of Gastrointestinal Surgery, 11(34), 8139–8148. https://doi.org/10.3748/wjg.v29.i34.5907